Rotigotine Transdermal System for the Treatment of Restless Legs Syndrome

• Happe S , TrenkwalderC: Role of dopamine receptor agonists in the treatment of restless legs syndrome.CNS Drugs18(1), 27–36 (2004).
   PubMed Web of Science ®Google Scholar
• Allen RP , PicchiettiD, HeningWAet al.: Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.Sleep Med.4, 101–119 (2003).
   PubMed Web of Science ®Google Scholar
• Montagna P : The treatment of restless legs syndrome.Neurol. Sci.28, S61–S66 (2007).
   PubMed Web of Science ®Google Scholar
• Oertel WH , TrenkwalderC, ZucconiMet al.: State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome.Mov. Disord.22(18), 466–475 (2007).
   Google Scholar
• Vignatelli L , BilliardM, ClarenbackPet al.: EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep.Eur. J. Neurol.13, 1049–1065 (2006).
   PubMed Web of Science ®Google Scholar
• Silber MH , EhrenbergBL, AllenRPet al.: An algorithm for the management of restless legs syndrome.Mayo Clin. Proc.79(7), 916–922 (2004).
   PubMed Web of Science ®Google Scholar
• Allen RP , EarleyCJ: Restless legs syndrome. A review of clinical and pathophysiologic features.J. Clin. Neurophysiol.18(2), 128–147 (2001).
   PubMed Web of Science ®Google Scholar
• Stiasny K , OertelWH, TrenkwalderC: Clinical symptomatology and treatment of restless legs syndrome and periodic limb movement disorder.Sleep Med. Rev.6, 253–265 (2002).
   PubMed Web of Science ®Google Scholar
• Priano L , GascoMR, MauroAL: Transdermal treatment options for neurological disorders. Impact on the elderly.Drugs Aging23(5), 357–375 (2006).
   PubMed Web of Science ®Google Scholar
• Guldenpfennig WM , PooleKH, SommervilleKWet al.: Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.Clin. Neuropharmacol.28(3), 106–110 (2005).
   PubMed Web of Science ®Google Scholar
• Chen JJ , SwopeDM: Pharmacotherapy for Parkinson‘s disease.Pharmacotherapy27(12 Pt 2), S161–S173 (2007).
   PubMed Web of Science ®Google Scholar
• Baker WL : Effect of nonergot dopamine agonists on symptoms of restless legs symptoms.Ann. Fam. Med.6, 253–262 (2008).
   PubMed Web of Science ®Google Scholar
• Pfitzenmeyer P , FoucherP, DennewaldGet al.: Pleuropulmonary changes induced by ergoline drugs.Eur. Respir. J.9, 1013–1019 (1996).
   PubMed Web of Science ®Google Scholar
• Horowski R , JahnichenS: Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT 2B receptor activation plays a crucial role.Mov. Disord.19, 1523–1524 (2004).
   PubMed Web of Science ®Google Scholar
• Foley P , GerlachM, DoubleKLet al.: Dopamine receptor agonists in the therapy of Parkinson‘s disease.J. Neural Transm.2111, 1375–1446 (2004).
   Google Scholar
• Tippman-Peikert MD , ParkJG, BoeveBFet al.: Pathological gambling in patients with restless legs syndrome treated with dopamine agonists.Neurology68, 301–303 (2007).
   PubMed Web of Science ®Google Scholar
• Driver-Dunckley ED , NobleBN, HentzJGet al.: Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome.Clin. Neuropharmacol.30, 249–255 (2007).
   PubMed Web of Science ®Google Scholar
• Dodd ML , KlosKJ, BowerJHet al.: Pathological gambling caused by drugs used to treat Parkinson disease.Arch. Neurol.62, 1377–1381 (2005).
   PubMed Web of Science ®Google Scholar
• Ryan M , SlevinJT: Restless legs syndrome.J. Pharm. Prac.20, 430–448 (2007).
   Google Scholar
• Trenkwalder C , PaullusW, WaltersWS: The restless legs syndrome.Lancet Neurol.4, 465–475 (2005).
   PubMed Web of Science ®Google Scholar
• Neupro Package Insert, Schwarz Pharma AG, Monheim, Germany (2004).
   Google Scholar
• Splinter MY : Rotigotine: transdermal dopamine agonist treatment of Parkinson‘s disease and restless legs syndrome.Ann. Pharmacother.41, 285–295 (2007).
   PubMed Web of Science ®Google Scholar
• Benes H : Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome.Sleep Med.7(1), 31–35 (2006).
   PubMed Web of Science ®Google Scholar
• Martin A : Drug product design. In: Physical Pharmacy. Lippincott Williams and Wilkins, NY, USA512–555 (1993).
   Google Scholar
• Jenner P : A novel dopamine agonist for the transdermal treatment of Parkinson‘s disease.Neurology65(Suppl. 1), S3–S5 (2005).
   PubMedGoogle Scholar
• Cawello W , WolffHM, MeulingWJet al.: Transdermal administration of radiolabelled 14C rotigotine by a patch formulation. A mass balance trial.Clin. Pharmacokinet.46(10), 851–857 (2007).
   PubMed Web of Science ®Google Scholar
• Stiasny-Kolster K , KohnenR, SchollmayerEet al.: Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study.Mov. Disord.19(12), 1432–1510 (2004).
   PubMed Web of Science ®Google Scholar
• Oertel WH , BenesH, Garcia-BorregueroDet al.: Efficacy of rotigotine transdermal system in severe RLS: a randomized, double blind, placebo controlled, 6-week dose-finding trial in Europe.Sleep Med.9(3), 228–239 (2008).
   PubMed Web of Science ®Google Scholar
• Trenkwalder C , BenesH, PoeweWet al.: Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial.Lancet Neurol.7, 595–604 (2008).
   PubMed Web of Science ®Google Scholar
• Oertel WH , BenesH, Garcia-BorregueroDet al.: One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.Sleep Med.9(8), 865–873 (2008).
   PubMed Web of Science ®Google Scholar
• Stiasny-Kolster K , Garcia-BorregueroD, SaletuBet al.: Rotigotine transdermal patch improves quality of life in restless leg syndrome. Presented at: 21st Annual Meeting Of Associated Professional Sleep Societies. 8–14 June, Minneapolis, MN, USA (2007).
   Google Scholar
• Oertel WH , BenesHH, Ferini-StrambiLet al.: Poster presentation. Objective assessment of efficacy and safety in idiopathic RLS: results from a 7-week sleep lab trial with transdermal rotigotine patch. Presented at: AAN 60th Annual Meeting. 12–19 April, Chicago, IL, USA (2008).
   Google Scholar
• Walters AS , LeBrocqC, DharAet al.: International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome.Sleep Med.4(2), 121–132 (2003).
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. 028 CGI. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. Guy W (Ed.). National Institute of Mental Health, MD, USA 217–222 (1976).
   Google Scholar
• Kohnen R , Stiasny-KolsterK, OertelWHet al.: Severity rating of restless legs syndrome: validation of the RLS-6 scales.Sleep27(Suppl.), A342 (2004).
   Google Scholar
• Albetz L , VallowSM, KirschJet al.: Validation of the restless legs syndrome quality of life questionnaire.Value Health8, 157–167 (2005).
   PubMed Web of Science ®Google Scholar
• Kohnen R , BenesH, HeinrichCRet al.: Development of the disease-specific restless legs syndrome quality of life (RSL-QoL) question-naire.Mov. Disord.17(Suppl. 5), P743 (2002).
   Google Scholar
• Hays RD , MartinSA, SestiAM, SpritzerKL: Psychometric properties of the medical outcomes study sleep measure.Sleep Med.6, 41–44 (2005).
   PubMed Web of Science ®Google Scholar
• Becker PM : Initial management of RLS augmentation with rotigotine patch.Sleep31, A265 (2008).
   Web of Science ®Google Scholar
• Ferini-Strambi L , AarskogD, PartinenMet al.: Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial.Sleep Med. (2008) (In press).
   Google Scholar
• Poewe WH , RascolO, QuinnNet al.: Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson‘s disease: a double-blind, double-dummy, randomized controlled trial.Lancet Neurol.6, 513–520 (2007).
   PubMed Web of Science ®Google Scholar
• LeWitt PA , BoroojerdiB, MacMahonDet al.: Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.Clin. Neuropharmacol.30(5), 256–264 (2007).
   PubMed Web of Science ®Google Scholar
• Schmidt WJ , LebsanftH, HeindlMet al.: Continuous versus pulsatile administration of rotigotine in 6-ODHA-lesioned rats: contralateral rotations and abnormal involuntary movements.J. Neural Transm.115, 1385–1392 (2008).
   PubMed Web of Science ®Google Scholar

Websites

• Clinicaltrials.gov www.clinicaltrials.gov (Accessed 8December2008).
   Google Scholar
• US FDA Safety Information and Adverse Event Reporting Program. www.fda.gov/medwatch (Accessed 24April2008).
   Google Scholar
• EMEA recommends changes in the storage conditions for Neupro (rotigotine). June 4, 2008. www.emea.europa.eu/humandocs/PDFs/EPAR/neupro/26875108en.pdf (Accessed 11February2009).
   Google Scholar